# Isola Therapeutics Inc.

Canonical: https://abierto.us/vendors/isola-therapeutics-inc-m3qdm72nme75

- UEI: M3QDM72NME75
- CAGE: 890E6
- Location: Minneapolis, MN
- Awards in window: 3 (3 transactions), $7,485,417 obligated, June 20, 2024 to April 27, 2026

## Awarding agencies

- Office of Assistant Secretary for Preparedness and Response: 2 awards, $7,485,417
- National Institutes of Health: 1 awards, $0

## Industries

- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology): $7,485,417
- 541714 Research and Development in Biotechnology (except Nanobiotechnology): $0

## Competition

- Full and Open Competition: 2 awards
- Full and Open Competition After Exclusion of Sources: 1 awards

## Solicitations won

- BARDA DRIVe EZ-BAA (EZBAA - 22-100-SOL-00003) (75A50126C00005), $7,485,417. https://abierto.us/opportunities/75a50126c00005

## Largest awards

- 75A50126C00005 (definitive contract): $7,485,417, Barda - Aspr / Daappo / Barda DCMA. The Purpose of This Award Is to Advance the Development of Isola'S Nebulization Therapy, a Medical Countermeasure Designed to Prevent and Treat Pulmonary Foam the Inhalation of Chemical Agents Causes.. https://www.usaspending.gov/award/CONT_AWD_75A50126C00005_7505_-NONE-_-NONE-/
- 75A50123C00031 (definitive contract): $0, Barda - Aspr / Daappo / Barda DCMA. R&D for Endobronchial Lavage (Ebl) to Prevent and Treat Lung Damage from Pulmonary Chemical Agents Aoi #15: Redirect (Repurposing Drugs in Response to Chemical Threats). https://www.usaspending.gov/award/CONT_AWD_75A50123C00031_7505_-NONE-_-NONE-/
- 75N91022C00018 (definitive contract): $0, NIH NCI. Phase I -Topic 431 - Drug Delivery by Endoesophageal Lavage (Eel) to Treat Esophageal Cancer. https://www.usaspending.gov/award/CONT_AWD_75N91022C00018_7529_-NONE-_-NONE-/

---
Source: USAspending.gov award data, keyed by UEI. Obligations in the window only. Cite https://abierto.us/vendors/isola-therapeutics-inc-m3qdm72nme75.